Late-Breaking Preclinical Data: Novel Anti-FasL mAb for Severe Dermatologic Conditions

Time: 9:00 am
day: Day One

Details:

  • Discover a novel non-immunosuppressive approach targeting FasL in severe blistering conditions with significant mortality rates 
  • Explore preclinical efficacy data from validated disease models using proprietary humanised FasL mouse platform 
  • Understand unique clinical considerations for underserved ‘orphan’ dermatology indications 

Speakers: